TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's Chairman and CEO, Michael S. Weiss, is scheduled to deliver a presentation on Monday, January 13, 2025, at 4:30 PM PT.

Investors and interested parties can access a live webcast of the presentation through the Events page in the Investors & Media section of TG Therapeutics' website. For those unable to attend the live presentation, a replay will be made available on the company's website following the event.

News Market Reaction – TGTX

+0.38%

+0.38% Session move

In the trading session that priced this news, TGTX gained 0.38%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PT

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 13, 2025, at 4:30 PM PT.

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG’s website following the event.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI^® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features, in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.

BRIUMVI^® is a registered trademark of TG Therapeutics, Inc.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

FAQ

When is TG Therapeutics (TGTX) presenting at the 2025 J.P. Morgan Healthcare Conference?

TG Therapeutics (TGTX) is scheduled to present at the conference on Monday, January 13, 2025, at 4:30 PM PT.

How can investors watch TG Therapeutics' (TGTX) J.P. Morgan Healthcare Conference presentation?

Investors can watch the live webcast through the Events page in the Investors & Media section of TG Therapeutics' website at http://ir.tgtherapeutics.com/events. A replay will also be available after the event.

Who will be presenting for TG Therapeutics (TGTX) at the 2025 J.P. Morgan Healthcare Conference?

Michael S. Weiss, TG Therapeutics' Chairman and Chief Executive Officer, will be presenting at the conference.

Will there be a replay available of TG Therapeutics' (TGTX) J.P. Morgan presentation?

Yes, a replay of the webcast will be made available on TG Therapeutics' website following the event.